OUR PRODUCTS
Each film-coated tablets contains:
12.5 mg carbidopa + 50 mg levodopa + 200 mg entacapone
25 mg carbidopa + 100 mg levodopa + 200 mg entacapone
31.25 mg carbidopa +125 mg levodopa + 200 mg entacapone
37.5 mg carbidopa + 150 mg levodopa + 200 mg entacapone
50 mg carbidopa + 200 mg levodopa + 200 mg entacapone
18.75 mg carbidopa + 75 mg levodopa + 200 mg entacapone
- Hypersensitivity to the active substances or to any of the excipients
- Severe hepatic impairment.
- Narrow-angle glaucoma.
- Pheochromocytoma.
- Coadministration with non-selective monoamine oxidase (MAO-A and MAO-B) inhibitors (e.g. phenelzine, tranylcypromine).
- Coadministration with a selective MAO-A inhibitor and a selective MAO-B inhibitor
- A previous history of Neuroleptic Malignant Syndrome (NMS) and/or non-traumatic rhabdomyolysis
- Antihypertensives: Symptomatic postural hypotension may occur when levodopa is added to the treatment of patients already receiving antihypertensive drugs. The dose of the antihypertensive agent may need to be adjusted.
- Antidepressants: In rare cases, reactions including hypertension and dyskinesia have been reported with concomitant use of tricyclic antidepressants.
- Other active substances: dopamine receptor antagonists (such as some antipsychotics and antiemetics), phenytoin and papaverine may reduce the therapeutic effect of levodopa. Patients taking these drugs with BarKLESS should be carefully monitored for loss of therapeutic response.
- Other Forms of Interactions: Since levodopa competes with some amino acids, BarKLESS absorption may be impaired in some patients on a high-protein diet.
- Levodopa and entacapone may chelate with iron in the gastrointestinal tract.
Treatment of adult patients with Parkinson's disease and end-of-dose motor fluctuations that have not stabilized on levodopa/dopa decarboxylase (DDC) inhibitor therapy.
Dosage:
- The optimum daily dose of Barclays should be determined by careful titration of levodopa in each patient.
- Clinical experience with daily doses above 1600 mg of entacapone is limited. The maximum recommended daily dose of ParKLESS tablets depends on the titer used. The maximum number of tablets to be used in a 24-hour period is lower with the highest ParKLESS tablet strength compared to the lower strength
- The maximum dose used for all titers except (50/200/200 mg): is 8 F.C. tablets per day.
- The maximum used dose of the caliber (50/200/200 mg) is 6 film-coated tablets per day.
- Elderly: No need to adjust the dose of ParKLESS for the elderly
- Hepatic insufficiency: ParKLESS should be administered with caution to patients with mild to moderate hepatic impairment. A dose reduction may be required in severe hepatic insufficiency.
- Renal impairment:ParKLESS Tablets should be administered with caution to patients with severe renal impairment, including those receiving hemodialysis.
Anorexia, thrombocytopenia, anorexia, anxiety, insomnia, depression, confusion, dyskinesia, tremor, dystonia, blurred vision, arrhythmia, orthostatic hypotension, shortness of breath, diarrhea, nausea, indigestion, dehydration Oral , abnormal liver function test , rash , hyperhidrosis , myalgia , arthralgia , peripheral edema , chest pain
PARKLESS 12.5/50/200 mg f.c.tablets..................( 187 / 2020 )
PARKLESS 18.75/75/200 mg f.c.tablets..................( 188 / 2020 )
PARKLESS 25/100/200 mg f.c.tablets..................( 189 / 2020 )
PARKLESS 31.25/125/200 mg f.c.tablets..................( 190 / 2020 )
PARKLESS 37.5/150/200 mg f.c.tablets..................( 191 / 2020 )
PARKLESS 50/200/200 mg f.c.tablets..................( 192 / 2020 )
A carton box containing 3 blister , each one contains 10 f.c.tablets.